Cargando…

SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations

PURPOSE: Endovascular therapy in the management of de novo common femoral disease remains controversial. Considerable interest has been generated in recent years due to recent technological advancement in the design of vascular stents. In particular, SUPERA (Abbot Vascular Inc, Santa Clara USA) sten...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Mary Jiayi, Gotra, Akshat, Tan, Kong Teng, Eisenberg, Naomi, Roche-Nagle, Graham, Mafeld, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003763/
https://www.ncbi.nlm.nih.gov/pubmed/35148653
http://dx.doi.org/10.1177/15385744211068648
_version_ 1784686183110934528
author Tao, Mary Jiayi
Gotra, Akshat
Tan, Kong Teng
Eisenberg, Naomi
Roche-Nagle, Graham
Mafeld, Sebastian
author_facet Tao, Mary Jiayi
Gotra, Akshat
Tan, Kong Teng
Eisenberg, Naomi
Roche-Nagle, Graham
Mafeld, Sebastian
author_sort Tao, Mary Jiayi
collection PubMed
description PURPOSE: Endovascular therapy in the management of de novo common femoral disease remains controversial. Considerable interest has been generated in recent years due to recent technological advancement in the design of vascular stents. In particular, SUPERA (Abbot Vascular Inc, Santa Clara USA) stents are designed to offer increased flexibility and less adverse interactions with the arterial wall, thus making it potentially better suited for common femoral lesions. However, despite such theoretical advantages, there is lack of data in its use in clinical practice. This study provides illustrative examples of SUPERA stents in different clinical settings and contributes to important clinical data for the overall efficacy and safety profile of endovascular interventions in common femoral artery (CFA) disease. MATERIALS AND METHODS: Retrospective analysis of all endovascular CFA procedures between January 1, 2011, and December 31, 2019, was conducted. Data collected included demographics, clinical symptoms, medical comorbidities, procedural characteristics, and immediate and short-term complications. Detailed analysis was performed on the stenting cohort. RESULTS: During our study period, a total of 69 patients underwent endovascular interventions involving the CFA at our institution, of which 16 patients had stenting procedures for a total of 18 stent deployments. Technical success was achieved in all stenting procedures. A total of 15 SUPERA stents were placed in 13 patients. No stent fractures were observed. Overall primary patency rate of SUPERA stents at the time of 12-month follow-up was 100% in patients who had a follow-up assessment (n = 12 stents). CONCLUSION: Endovascular intervention of the CFA is an evolving topic in the interventional radiology and vascular surgery community. Recent development of newer generation of devices such as SUPERA peripheral stents offers significant potential benefits given their inherent design. Despite the theoretically promising design of the SUPERA, there is a lack of data to support its use. This study contributes important patient-level data for SUPERA stent deployments.
format Online
Article
Text
id pubmed-9003763
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90037632022-04-13 SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations Tao, Mary Jiayi Gotra, Akshat Tan, Kong Teng Eisenberg, Naomi Roche-Nagle, Graham Mafeld, Sebastian Vasc Endovascular Surg Original Articles PURPOSE: Endovascular therapy in the management of de novo common femoral disease remains controversial. Considerable interest has been generated in recent years due to recent technological advancement in the design of vascular stents. In particular, SUPERA (Abbot Vascular Inc, Santa Clara USA) stents are designed to offer increased flexibility and less adverse interactions with the arterial wall, thus making it potentially better suited for common femoral lesions. However, despite such theoretical advantages, there is lack of data in its use in clinical practice. This study provides illustrative examples of SUPERA stents in different clinical settings and contributes to important clinical data for the overall efficacy and safety profile of endovascular interventions in common femoral artery (CFA) disease. MATERIALS AND METHODS: Retrospective analysis of all endovascular CFA procedures between January 1, 2011, and December 31, 2019, was conducted. Data collected included demographics, clinical symptoms, medical comorbidities, procedural characteristics, and immediate and short-term complications. Detailed analysis was performed on the stenting cohort. RESULTS: During our study period, a total of 69 patients underwent endovascular interventions involving the CFA at our institution, of which 16 patients had stenting procedures for a total of 18 stent deployments. Technical success was achieved in all stenting procedures. A total of 15 SUPERA stents were placed in 13 patients. No stent fractures were observed. Overall primary patency rate of SUPERA stents at the time of 12-month follow-up was 100% in patients who had a follow-up assessment (n = 12 stents). CONCLUSION: Endovascular intervention of the CFA is an evolving topic in the interventional radiology and vascular surgery community. Recent development of newer generation of devices such as SUPERA peripheral stents offers significant potential benefits given their inherent design. Despite the theoretically promising design of the SUPERA, there is a lack of data to support its use. This study contributes important patient-level data for SUPERA stent deployments. SAGE Publications 2022-02-11 2022-05 /pmc/articles/PMC9003763/ /pubmed/35148653 http://dx.doi.org/10.1177/15385744211068648 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Tao, Mary Jiayi
Gotra, Akshat
Tan, Kong Teng
Eisenberg, Naomi
Roche-Nagle, Graham
Mafeld, Sebastian
SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title_full SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title_fullStr SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title_full_unstemmed SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title_short SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations
title_sort supera stenting in the common femoral artery: early experience and practical considerations
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003763/
https://www.ncbi.nlm.nih.gov/pubmed/35148653
http://dx.doi.org/10.1177/15385744211068648
work_keys_str_mv AT taomaryjiayi superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations
AT gotraakshat superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations
AT tankongteng superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations
AT eisenbergnaomi superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations
AT rochenaglegraham superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations
AT mafeldsebastian superastentinginthecommonfemoralarteryearlyexperienceandpracticalconsiderations